骨细胞作为骨质疏松症治疗的靶点。
The osteocyte as a therapeutic target in the treatment of osteoporosis.
作者信息
Rochefort Gaël Y
机构信息
EA 2496, Faculté de Chirurgie Dentaire, Université Paris Descartes, 1 rue Maurice Arnoux, 92120 Montrouge, France.
出版信息
Ther Adv Musculoskelet Dis. 2014 Jun;6(3):79-91. doi: 10.1177/1759720X14523500.
Abstract
Osteoporosis is characterized by a low bone-mineral density associated with skeletal fractures. The decrease in bone-mineral density is the consequence of an unbalanced bone-remodeling process, with higher bone resorption than bone formation. The orchestration of the bone-remodeling process is under the control of the most abundant cell in bone, the osteocyte. Functioning as an endocrine cell, osteocytes are also a source of soluble factors that not only target cells on the bone surface, but also target distant organs. Therefore, any drugs targeting the osteocyte functions and signaling pathways will have a major impact on the bone-remodeling process. This review discusses potential advances in drug therapy for osteoporosis, including novel osteocyte-related antiresorptive and anabolic agents that may become available in the coming years.
摘要
骨质疏松症的特征是骨矿物质密度低并伴有骨骼骨折。骨矿物质密度的降低是骨重塑过程失衡的结果，骨吸收高于骨形成。骨重塑过程受骨中最丰富的细胞——骨细胞的控制。作为一种内分泌细胞，骨细胞也是可溶性因子的来源，这些因子不仅作用于骨表面的细胞，还作用于远处的器官。因此，任何针对骨细胞功能和信号通路的药物都将对骨重塑过程产生重大影响。本文综述了骨质疏松症药物治疗的潜在进展，包括未来几年可能出现的与骨细胞相关的新型抗吸收和促合成药物。
相似文献
1
The osteocyte as a therapeutic target in the treatment of osteoporosis.骨细胞作为骨质疏松症治疗的靶点。
Ther Adv Musculoskelet Dis. 2014 Jun;6(3):79-91. doi: 10.1177/1759720X14523500.
2
Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy.骨建模减少与骨重塑失衡：抗吸收和促合成治疗的靶点
Handb Exp Pharmacol. 2020;262:423-450. doi: 10.1007/164_2020_354.
3
Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?用于合成代谢和抗吸收药物的双向选择性骨靶向递送：一种治疗骨质疏松症的新型联合疗法？
Med Hypotheses. 2014 Dec;83(6):694-6. doi: 10.1016/j.mehy.2014.09.020. Epub 2014 Oct 13.
4
Perspectives on osteoporosis therapies.骨质疏松症治疗的观点。
J Endocrinol Invest. 2015 Mar;38(3):303-11. doi: 10.1007/s40618-014-0236-9. Epub 2015 Jan 11.
5
The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.破骨细胞——罕见骨病治疗新靶点
Front Endocrinol (Lausanne). 2020 Jul 8;11:405. doi: 10.3389/fendo.2020.00405. eCollection 2020.
6
Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.绝经后骨质疏松症抗吸收治疗的作用机制
Endocr Regul. 2003 Dec;37(4):225-38.
7
Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.骨质疏松症治疗中骨合成代谢药物的最新进展：原理、现状和展望。
J Clin Endocrinol Metab. 2012 Feb;97(2):311-25. doi: 10.1210/jc.2011-2332. Epub 2012 Jan 11.
8
YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular Remodeling.YAP和TAZ介导骨细胞陷窝周围/小管重塑。
J Bone Miner Res. 2020 Jan;35(1):196-210. doi: 10.1002/jbmr.3876. Epub 2019 Oct 14.
9
Differences in osteocyte density and bone histomorphometry between men and women and between healthy and osteoporotic subjects.男性与女性之间以及健康受试者与骨质疏松症受试者之间骨细胞密度和骨组织形态计量学的差异。
Calcif Tissue Int. 2005 Nov;77(5):291-6. doi: 10.1007/s00223-005-0043-6. Epub 2005 Nov 16.
10
Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.地舒单抗治疗期间骨硬度升高，停药期间破骨细胞活性持续降低。
Front Endocrinol (Lausanne). 2020 May 15;11:250. doi: 10.3389/fendo.2020.00250. eCollection 2020.
引用本文的文献
1
LRP4 and Agrin Are Modulated by Cartilage Degeneration and Involved in β-Catenin Signaling in Human Articular Chondrocytes.LRP4和聚集蛋白受软骨退变调控并参与人关节软骨细胞中的β-连环蛋白信号传导。
Int J Mol Sci. 2025 Jan 24;26(3):1007. doi: 10.3390/ijms26031007.
2
Water Extract of Nakai Inhibits Osteoclast Differentiation and Alleviates Ovariectomy-Induced Bone Loss.中田水提取物抑制破骨细胞分化并缓解卵巢切除诱导的骨丢失。
Int J Mol Sci. 2024 Oct 29;25(21):11616. doi: 10.3390/ijms252111616.
3
Editorial: Model organisms and experimental models: opportunities and challenges in musculoskeletal physiology.社论：模式生物与实验模型：肌肉骨骼生理学中的机遇与挑战
Front Physiol. 2023 Dec 8;14:1346490. doi: 10.3389/fphys.2023.1346490. eCollection 2023.
4
Review on the protective activity of osthole against the pathogenesis of osteoporosis.蛇床子素对骨质疏松症发病机制的保护作用综述
Front Pharmacol. 2023 Aug 23;14:1236893. doi: 10.3389/fphar.2023.1236893. eCollection 2023.
5
Signaling pathways associated with bone loss in inflammatory bowel disease.与炎症性肠病骨质流失相关的信号通路。
Ann Gastroenterol. 2023 Mar-Apr;36(2):132-140. doi: 10.20524/aog.2023.0785. Epub 2023 Feb 8.
6
Direct Assessment of Rabbit Cortical Bone Basic Multicellular Unit Longitudinal Erosion Rate: A 4D Synchrotron-Based Approach.直接评估兔皮质骨基本多细胞单位纵向侵蚀率：一种基于 4D 同步加速器的方法。
J Bone Miner Res. 2022 Nov;37(11):2244-2258. doi: 10.1002/jbmr.4700. Epub 2022 Oct 3.
7
Accumulation of advanced oxidation protein products contributes to age-related impairment of gap junction intercellular communication in osteocytes of male mice.晚期氧化蛋白产物的积累导致雄性小鼠骨细胞中与年龄相关的缝隙连接细胞间通讯受损。
Bone Joint Res. 2022 Jul;11(7):413-425. doi: 10.1302/2046-3758.117.BJR-2021-0554.R2.
8
The Mechanosensory Role of Osteocytes and Implications for Bone Health and Disease States.骨细胞的机械感觉作用及其对骨骼健康和疾病状态的影响。
Front Cell Dev Biol. 2022 Feb 21;9:770143. doi: 10.3389/fcell.2021.770143. eCollection 2021.
9
Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?骨质疏松症的治疗方法——哪种药丸组合是最差的？
Int J Mol Sci. 2022 Jan 26;23(3):1393. doi: 10.3390/ijms23031393.
10
Osteoporosis therapies and their mechanisms of action (Review).骨质疏松症治疗方法及其作用机制（综述）
Exp Ther Med. 2021 Dec;22(6):1379. doi: 10.3892/etm.2021.10815. Epub 2021 Sep 28.
本文引用的文献
1
Paget disease of bone: A classic case report.骨佩吉特病：一例典型病例报告。
Contemp Clin Dent. 2013 Apr;4(2):227-30. doi: 10.4103/0976-237X.114858.
2
Pregnancy-associated osteoporosis with a heterozygous deactivating LDL receptor-related protein 5 (LRP5) mutation and a homozygous methylenetetrahydrofolate reductase (MTHFR) polymorphism.妊娠相关性骨质疏松症伴杂合性失活性低密度脂蛋白受体相关蛋白5（LRP5）突变和纯合性亚甲基四氢叶酸还原酶（MTHFR）多态性。
J Bone Miner Res. 2014 Apr;29(4):922-8. doi: 10.1002/jbmr.2095.
3
The roles of canonical and non-canonical Wnt signaling in human de-differentiated articular chondrocytes.经典和非经典Wnt信号通路在人去分化关节软骨细胞中的作用
Biotech Histochem. 2014 Jan;89(1):53-65. doi: 10.3109/10520295.2013.819123. Epub 2013 Aug 1.
4
Osteocytes are not only mechanoreceptive cells.成骨细胞不仅是机械感受细胞。
Int J Numer Method Biomed Eng. 2013 Oct;29(10):1082-8. doi: 10.1002/cnm.2561. Epub 2013 Jun 17.
5
Time-dependent effects of sclerostin antibody on a mouse fracture healing model.硬化蛋白抗体对小鼠骨折愈合模型的时间依赖性影响。
J Musculoskelet Neuronal Interact. 2013 Jun;13(2):178-84.
6
Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.抗硬骨素抗体抑制硬骨素内化和硬骨素介导的 Wnt/LRP6 信号转导拮抗作用。
PLoS One. 2013 Apr 29;8(4):e62295. doi: 10.1371/journal.pone.0062295. Print 2013.
7
The osteocyte: an endocrine cell ... and more.骨细胞：一种内分泌细胞……以及更多功能。
Endocr Rev. 2013 Oct;34(5):658-90. doi: 10.1210/er.2012-1026. Epub 2013 Apr 23.
8
Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH.甲状旁腺激素（PTH）受体-1磷酸化在调节 PTH 急性反应中的关键作用。
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5864-9. doi: 10.1073/pnas.1301674110. Epub 2013 Mar 26.
9
Calcium-sensing receptor-dependent activation of CREB phosphorylation in HEK293 cells and human parathyroid cells.钙敏感受体依赖性激活 HEK293 细胞和人甲状旁腺细胞中 CREB 的磷酸化。
Am J Physiol Endocrinol Metab. 2013 May 15;304(10):E1097-104. doi: 10.1152/ajpendo.00054.2013. Epub 2013 Mar 26.
10
A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans.一种半机械论模型，用于描述在人类中施用钙敏感受体激动剂 JTT-305/MK-5442 后 PTH 向血浆中释放的时程。
J Bone Miner Res. 2013 Aug;28(8):1830-6. doi: 10.1002/jbmr.1900.
Zotero 插件